Related references
Note: Only part of the references are listed.Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis
Lukas P. Frenzel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo
L. P. Mueller et al.
CANCER GENE THERAPY (2011)
The role of dietary polyphenols in tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis for cancer chemoprevention
Ewelina Szliszka et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2011)
Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases
Raquel Tognon et al.
JOURNAL OF CLINICAL PATHOLOGY (2011)
BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients
D. D. De Carvalho et al.
ONCOGENE (2011)
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway
Rosa Lapalombella et al.
BLOOD (2010)
FOXO3A as a key molecule for all-trans retinoic acid-induced granulocytic differentiation and apoptosis in acute promyelocytic leukemia
Yasuhiko Sakoe et al.
BLOOD (2010)
Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature
Cristiana Lavazza et al.
BLOOD (2010)
Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia
Lei Yang et al.
BLOOD (2010)
Leukemia regression by vascular disruption and antiangiogenic therapy
Gerard J. Madlambayan et al.
BLOOD (2010)
Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients
M. Russo et al.
BRITISH JOURNAL OF CANCER (2010)
TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population
M. R. Loebinger et al.
BRITISH JOURNAL OF CANCER (2010)
Adipose-Derived Mesenchymal Stem Cells as Stable Source of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Delivery for Cancer Therapy
Giulia Grisendi et al.
CANCER RESEARCH (2010)
TRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of MCL-1
J. K. Son et al.
CELL DEATH AND DIFFERENTIATION (2010)
TRAIL receptor signaling and therapeutics
Junaid Abdulghani et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2010)
p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal
Zhen Zhao et al.
GENES & DEVELOPMENT (2010)
Lipopolysaccharide-induced expression of TRAIL promotes dendritic cell differentiation
Young S. Cho et al.
IMMUNOLOGY (2010)
Vγ9Vγ2 T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells
Matilde D'Asaro et al.
JOURNAL OF IMMUNOLOGY (2010)
Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells
Francesca M. Rossi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Serum N-glycome biomarker for monitoring development of DENA-induced hepatocellular carcinoma in rat
Meng Fang et al.
MOLECULAR CANCER (2010)
Inhibition of Constitutive Activation of STAT3 by Curcurbitacin-I (JSI-124) Sensitized Human B-Leukemia Cells to Apoptosis
Ganchimeg Ishdorj et al.
MOLECULAR CANCER THERAPEUTICS (2010)
The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo
David M. Lucas et al.
PLOS ONE (2010)
Novel HTS Strategy Identifies TRAIL-Sensitizing Compounds Acting Specifically Through the Caspase-8 Apoptotic Axis
Darren Finlay et al.
PLOS ONE (2010)
Irradiation Enhances the Tumor Tropism and Therapeutic Potential of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Secreting Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Glioma Therapy
Seong Muk Kim et al.
STEM CELLS (2010)
Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP
Soo-Jung Park et al.
BIOCHEMICAL JOURNAL (2009)
Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance
Melanie Fakler et al.
BLOOD (2009)
Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival
Tiffany Ting-Fang Shih et al.
BLOOD (2009)
Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib
Agnes S. M. Yong et al.
BLOOD (2009)
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation
Stephan Metzelder et al.
BLOOD (2009)
A Novel Paradigm to Trigger Apoptosis in Chronic Lymphocytic Leukemia
Sandra Loeder et al.
CANCER RESEARCH (2009)
Role of full-length osteoprotegerin in tumor cell biology
G. Zauli et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2009)
p65 Activity and ZAP-70 Status Predict the Sensitivity of Chronic Lymphocytic Leukemia Cells to the Selective IκB Kinase Inhibitor BMS-345541
Monica Lopez-Guerra et al.
CLINICAL CANCER RESEARCH (2009)
TNF-related apoptosis-inducing ligand: Signalling of a 'smart' molecule
Fabio Manzo et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Stem cells are resistant to TRAIL receptor-mediated apoptosis
Eva Szegezdi et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis
Satoshi Inoue et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells
H. Hasegawa et al.
LEUKEMIA (2009)
Identification of molecular targets for selective elimination of TRAIL-resistant leukemia cells. From spots to in vitro assays using TOP15 charts
Jiri Petrak et al.
PROTEOMICS (2009)
Antitumor activity of bortezomib alone and in combination with trail in human acute myeloid leukemia
Concetta Conticello et al.
ACTA HAEMATOLOGICA (2008)
Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5
Bing Z. Carter et al.
BLOOD (2008)
Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells
Pier Luigi Tazzari et al.
CANCER RESEARCH (2008)
Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors
Ebenezer David et al.
CLINICAL CANCER RESEARCH (2008)
Tumor necrosis factor-related apoptosis-inducing ligand and the regulation of hematopoiesis
Paola Secchiero et al.
CURRENT OPINION IN HEMATOLOGY (2008)
The MDM2 inhibitor nutlins as an innovative therapeutic tool for the treatment of haematological malignancies
Paola Secchiero et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Anticancer alkylphospholipids: Mechanisms of action, cellular sensitivity and resistance, and clinical prospects
Wim J. van Blitterswijk et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Promotes Migration of Human Bone Marrow Multipotent Stromal Cells
Paola Secchiero et al.
STEM CELLS (2008)
TNF-related apoptosis-inducing ligand (TRAIL) is expressed throughout myeloid development, resulting in a broad distribution among neutrophil granules
Mark P. Simons et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2008)
Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand
Satoru Kikuchi et al.
CANCER SCIENCE (2007)
TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2
Alessandro Natoni et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
MCL-1 as a buffer for proapoptotic BCL-2 family members during TRAIL-induced apoptosis - A mechanistic basis for sorafenib (bay 43-9006)-induced trail sensitization
Xue Wei Meng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of zap-70
Paola Secchiero et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2007)
The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with mcl-1 and cFLIPL down-regulation
Roberto R. Rosato et al.
CANCER RESEARCH (2007)
M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis
Roberta Riccioni et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response
Laurence Lagneaux et al.
EXPERIMENTAL HEMATOLOGY (2007)
A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) through 15-deoxy-Δ12,14 prostaglandin J2 production
Hiroo Hasegawa et al.
BLOOD (2007)
Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo
Giorgio Zauli et al.
BLOOD (2007)
Reduction of TRAIL-induced McI-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death
M. Stacey Ricci et al.
CANCER CELL (2007)
Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia
Shannon E. Mullican et al.
NATURE MEDICINE (2007)
Treatment with IFNα in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients
Hideo Tanaka et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells
Paola Secchiero et al.
CURRENT DRUG METABOLISM (2007)
Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer
Karen T. Liby et al.
NATURE REVIEWS CANCER (2007)
Targeting TRAIL agonistic receptors for cancer therapy
Carmelo Carlo-Stella et al.
CLINICAL CANCER RESEARCH (2007)
Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts
Consuelo Gajate et al.
BLOOD (2007)
Antiangiogenic activity of the MDM2 antagonist nutlin-3
Paola Secchiero et al.
CIRCULATION RESEARCH (2007)
The role of death receptor ligands in shaping tumor microenvironment
Theresa L. Whiteside
IMMUNOLOGICAL INVESTIGATIONS (2007)
Resistance of infant leukemia with MLL rearrangement to tumor necrosis factor-related apoptosis-inducing ligand:: a possible mechanism for poor sensitivity to antitumor immunity
T. Inukai et al.
LEUKEMIA (2006)
Wogonin sensitizes resistant malignant cells to TNFα- and TRAIL-induced apoptosis
Stefanie C. Fas et al.
BLOOD (2006)
The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells
Albert F. Kabore et al.
APOPTOSIS (2006)
Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis
Satoshi Inoue et al.
CANCER RESEARCH (2006)
Dihydroflavonol BB-1, an extract of natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells
H Hasegawa et al.
BLOOD (2006)
Cutting edge: TRAIL deficiency accelerates hematological malignancies
N Zerafa et al.
JOURNAL OF IMMUNOLOGY (2005)
Functional expression of TRAIL and TRAIL-R2 during human megakaryocytic development
E Melloni et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2005)
TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release
P Secchiero et al.
BLOOD (2005)
Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes
D Campioni et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
A Nebbioso et al.
NATURE MEDICINE (2005)
Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L
R Di Pietro et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2004)
Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity
P Mirandola et al.
BLOOD (2004)
IFNα-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells
C Tecchio et al.
BLOOD (2004)
Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL
WS Suh et al.
LEUKEMIA (2003)
Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway
P Secchiero et al.
BLOOD (2002)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
PD Kottaridis et al.
BLOOD (2001)
Share Paper
